Gland Pharma Limited Bonus

Gland Pharma Limited has not has not announced any bonus since 29 Aug, 2023

₹1625.10₹1625.10-30.20 (-1.82%)

Last updated on 15 Mar, 2026 | 12:00 IST

Gland Pharma Limited Bonus Share Details

Bonus Ratio	Ex-Bonus Date	Record Date	Announcement Date
No data found

*Disclaimer: The information listed is solely for research purposes and are not recommendations. Please conduct your own research before making any investment decisions.

FAQs

Why does Gland Pharma issue bonus shares?

Gland Pharma issues bonus shares to reward shareholders, capitalise reserves and increase the liquidity of their shares in the market.

Who is eligible to receive Gland Pharma bonus shares?

Shareholders of Gland Pharma who own the company shares before the ex-date are eligible to receive bonus shares.

Has Gland Pharma ever issued bonus shares?

No, Gland Pharma has not issued any bonus shares in last 2023-2025

What was the last bonus issue ratio for Gland Pharma?

Gland Pharma hasn’t had any bonus shares in last 2023-2025

Gland Pharma Limited Bonus Shares

Attention Investors & Disclaimer

Upstox Securities Pvt. Ltd.: SEBI Registration No. INZ000315837 | NSE TM Code: 13942 | BSE TM Code: 6155 | MCX TM Code: 46510 | CDSL Reg No.: IN-DP-761-2024 | CIN: U65100DL2021PTC376860 | Compliance Officer: Mr. Kapil Jaikalyani. Tel No.: (022) 24229920. Email ID: compliance@upstox.com | Registered Address: 809, New Delhi House, Barakhamba Road, Connaught Place, New Delhi - 110001 | Correspondence Address: 30th Floor, Sunshine Tower, Senapati Bapat Marg, Dadar (West), Mumbai - 400013. | For any complaints, email at complaints@upstox.com and complaints.mcx@upstox.com.

About the Company

Upstox Securities Private Limited is a wholly owned subsidiary of RKSV Securities India Private Limited.

SEBI Scores

Procedure to file a complaint on SEBI SCORES: Register on the SCORES portal. Mandatory details for filing complaints on SCORES include: Name, PAN, Address, Mobile Number, and E-mail ID. Benefits include effective communication and speedy redressal of grievances. Please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI, along with our Terms of Use and Privacy Policy.

Attention to Investors

Smart Online Dispute Resolution: SEBI has established an Online Dispute Resolution Portal (ODR Portal) for resolving disputes in the Indian Securities Market. This circular streamlines the existing dispute resolution mechanism, offering online conciliation and arbitration, benefiting investors and listed companies.

Collateral: Clearing Corporation has provided a web based facility that allows clients to view their disaggregated collateral placed. Please access them via these links NCL | ICCL

Kindly refer to the Advisory Guidelines issued by Exchanges for trading

Investment Disclaimer

Disclaimer: Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

*Brokerage will not exceed the SEBI prescribed limit and Annual Maintenance charges are free upto one year for users onboarded from 14-Feb-2025 onwards

We do not authorize any person or organization to conduct trades on behalf of Upstox customers. If you find anyone claiming to be part of Upstox or RKSV or representing Upstox/RKSV and offering such services, please send us an email at complaints@upstox.com

Use of New Validated UPI Handles in the Securities Market | CDSL voting on motions moved by Listed Companies

Insurance

RKSV Securities India Pvt. Ltd. ("Upstox") with registered office at 807, New Delhi House Barakhamba Road Connaught Place, New Delhi, Delhi-110001, Delhi (CIN: U74900DL2009PTC189166) is a Corporate Agent registered with Insurance Regulatory and Development Authority of India (IRDAI) (Category: Composite, IRDAI Regn No.-: CA0918 valid till 05-03-2027).

Disclosures/Disclaimers for Insurance Products

Email ID: insurancesupport@rksv.in

Bima Bharosa Portal: https://bimabharosa.irdai.gov.in/

IRDAI: https://irdai.gov.in/

Insurance Ombudsman: https://www.cioins.co.in/